Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

By M. Thase, A. Entsuah, R. Rudolph. British Journal of Psychiatry, 2001

800 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. (2008, unknown): “Income, median (range), thousands $ 60 (8-500) 62 (0-250) .”
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder (2006, background): “…et al, 2004; Fava et al, 2004; Goldstein et al, 2004; Montgomery et al, 2004; Nelson et al, 2004; Perlis et al, 2004; Prudic et al, 2004; Trivedi et al, 2004a) and in pooled or meta-analyses (Lepola et al, 1998; Beasley et al, 2000; Entsuah et al, 2001; Thase et al, 2001; Dawson et al, 2004).”
Sequenced Treatment Alternatives to Relieve Depression (2018, background): “First line pharmacotherapy recommended by the WAPDC and RANZCP is an SSRI, mirtazapine or venlafaxine, however pooled results of doubleblind randomised controlled trials estimate that remission rates are only 30-45%.(2) Currently there is little evidence to guide practitioners who wish to venture in”
Handbook of Dynamic Psychotherapy for Higher Level Personality Pathology (2007, background): “Because fewer than 50% of depressed patients achieve remission with the first selective serotonin reuptake inhibitor (SSRI) prescribed (Thase et al. 2001), many patients will require ongoing medication management that involves either switching medication or augmenting the original treatment prescrib”